Premium
Erythroleukemia and other hematologic complications of intensive therapy in long‐term survivors of small cell lung cancer
Author(s) -
Bradley Edward C.,
Schechter Geraldine P.,
Matthews Mary J.,
WhangPeng Jacqueline,
Cohen Martin H.,
Bunn Paul A.,
Ihde Daniel C.,
Minna John D.
Publication year - 1982
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19820115)49:2<221::aid-cncr2820490204>3.0.co;2-#
Subject(s) - medicine , leukopenia , pancytopenia , sideroblastic anemia , chemotherapy , macrocytic anemia , radiation therapy , anemia , leukemia , cancer , lung cancer , small cell carcinoma , gastroenterology , pediatrics , bone marrow
Eight patients with small cell bronchogenic carcinoma treated with intensive combination chemotherapy, with and without radiotherapy, have been followed for a minimum of two and a half years without relapse. One patient, after a prodrome of macrocytic sideroblastic anemia, leukopenia, and thrombocytopenia, experienced erythroleukemia 34 months after starting chemotherapy, and cytogenetic studies revealed extensive chromosomal abnormalities. Another patient had persistent macrocytic anemia and pancytopenia two years after cessation of therapy. The remaining six patients have normal peripheral blood smears and cell counts. A significant incidence of preleukemic syndromes and acute leukemia appearing as late complications in intensively treated small cell lung cancer patients requires confirmation in larger series of long‐term survivors. Prospective determination of marrow karyotype abnormalities may help to identify patients at greatest risk for developing secondary leukemia.